Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine PK in Erector Spinae Plane Block
NCT03874806Phase 4Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ropivacaine in postoperative pain (2 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Maximum Plasma Concentration (Cmax) at 28 hours, Time to Maximum Plasma Concentration (Tmax) at 28 hours and 2 more. Planned start Jul 2019; status: withdrawn.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03874806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874806.